Wearable Ultrasound: A $30M Market Set to Grow Fivefold by 2032

Summary: Ultrasound is moving out of the scanning room and onto the patient's body. The companies that turned FDA clearances into hospital contracts and home-care programmes during 2025–26 now hold the early lead in a category. Market Research Reports sizes at $30.33 million today and up to $164 million by 2032.

Research in Brief

• Small base, steep curve. The global wearable ultrasound devices market stands at US$30.33 million (2025) and compounds at a 25.9% CAGR, reaching US$152.1 million (base case) to US$164 million (bull case) by 2032. That is 5.0x to 5.4x the base year. (Market Research Reports)
• Medtech-grade unit economics. The industry carries a 55–70% average gross margin, with average product prices of US$300–2,500 per unit (Market Research Reports).
• The regulatory moat is already being built. All four profiled leaders hold FDA clearances or government-backed programmes. That is the hardest asset for a late entrant to copy.
• Two proven beachheads. MRR identifies ICU blood-flow monitoring and home rehabilitation therapy as the most mature applications. Public company disclosures show both now running at multi-site, multi-country scale.
• The next leg is platform. Imaging patches built on polymer MEMS transducers (the PMUT/CMUT routes in MRR's segmentation) are attracting partnerships with Medtronic and federal R&D money from ARPA-H.

Why Now: Three Forces Opening the Market

1. Care is moving out of the hospital. MRR notes that health systems worldwide are increasingly backing remote patient monitoring, outpatient management and continuous monitoring. Wearable ultrasound is the first imaging modality that fits that model. A patch stays on the patient, and the data travels to the clinician.

2. The components have caught up with the idea. MRR points to three supply-side enablers that are accelerating commercialisation:

• advances in flexible piezoelectric materials
• MEMS ultrasound manufacturing
• edge-AI semiconductors

Supply has moved from lab prototypes to clinically validated products.

3. Federal R&D money is pulling the category forward. In July 2026, ARPA-H's Making Obstetrics Care Smart (MOCS) programme funded a project worth up to US$8.4 million, led by UNC Charlotte with Sonus Microsystems as the wearable-ultrasound partner. NIH SBIR grants funded clinical development of ZetrOZ's therapeutic wearable . NATO's DIANA accelerator is backing Flosonics' patch for early shock detection . Non-dilutive public capital is lowering the risk of the early clinical work for private investors.

Where the Money Is

Implied volume math (illustrative). At MRR's US$300–2,500 price band:

• 2025: the US$30.33M market equals roughly 12,000 to 101,000 units shipped.
• 2032 (base case): US$152.1M equals roughly 61,000 to 507,000 units.

Either way, the category is moving from thousands of units to hundreds of thousands. That is the volume range where automated transducer manufacturing starts to matter.

Two Scenarios to 2032

The US$11.9M gap between the two cases is the value of execution. The catalyst calendar below lists the public milestones that would move the market toward the bull case.

Ways to Play It

The four players MRR profiles map onto four distinct investor theses.

1. Pulsenmore Ltd. — The listed home-care platform (NASDAQ / TASE: PLSM)

What it does. Pulsenmore makes a smartphone-connected home ultrasound cradle. Expectant mothers self-scan, and clinicians review the images remotely.

Public milestones.

• FDA De Novo authorisation for the Pulsenmore ES (November 2025). Before this, the platform had already supported more than 200,000 patient scans across Israel, Europe, Brazil and Australia.
• FY2025 revenue of US$12.5M. This includes US$9.6M of one-time revenue from its GE HealthCare settlement, which puts core revenue at about US$2.9M. The net loss narrowed to US$5M from US$10M, and liquid assets stood at US$21.7M at year-end.
• H1 2026 revenue of NIS 6.1M (about US$2M), up 53% year over year. It sold about 4,265 devices, launched US commercial operations, and signed its first US provider agreements.
• US business model, from its own investor deck: device sales of about US$1,000 per single-pregnancy unit make up 60% of the mix, and recurring clinician-dashboard SaaS makes up 40% 

CEO briefing. Founder-CEO Dr. Elazar Sonnenschein frames 2025 as the shift from regulatory approval to commercial execution. He positions the company for "a significant market opportunity in remote prenatal diagnostics" 

Watch. The company's FDA authorisation video (YouTube) and its app-guided scanning demo (YouTube).

MRR's Take: Pulsenmore is the purest listed exposure to MRR's Home Healthcare segment. The one-time GE revenue is now in the past, so the investable number is the core run-rate and the growing SaaS share. Its in-house automated transducer lines give it a manufacturing cost edge as US volumes scale.

2. Flosonics Medical — The ICU standard-setter (private, venture-backed)

What it does. FloPatch is a wireless, single-use Doppler ultrasound patch worn on the neck. It measures carotid blood flow to guide IV fluid decisions in sepsis and critical care.

Public milestones.

• Capital raised: a US$14M Series B (2021), a US$20M Series C (March 2024) led by New Leaf Venture Partners, and C$7.5M (about US$5.2M) of venture debt from RBCx (March 2025) .
• Health-system adoption:
  • Sutter Health expanded FloPatch to three more Bay Area hospitals in April 2026, after six campuses in the prior year.
  • The Mount Sinai Hospital became its first East Coast site in 2025.
  • Riverside University Health System and St. Michael's Hospital in Toronto are also on the reference list.
• Purchasing access: a Vizient Innovative Technology contract (March 2026), which opens group-purchasing channels across US hospitals .
• Federal channel: a partnership with Lovell Government Services to serve federal health systems, and backing from NATO DIANA for battlefield shock detection.

CEO briefing. Co-founder and CEO Joe Eibl presents Sutter's multi-site rollout as evidence that "wearable, real-time technologies play a transformative role in patient care" . The Series C proceeds go to commercial growth, expanded indications and evidence generation.

MRR's Take: Flosonics owns the most mature use case in MRR's data, ICU Monitoring. Its consumable, single-use model produces recurring revenue per patient episode. The Vizient contract is the inflection to watch: it turns one hospital at a time into a network-wide purchasing decision. That profile suits a strategic acquirer in hemodynamic monitoring.

3. ZetrOZ Systems — The cash-generating therapy pioneer (private)

What it does. The sam® device delivers multi-hour, low-intensity "sustained acoustic medicine" for musculoskeletal pain and soft-tissue healing, worn at home.

Public milestones.

• First FDA 510(k) clearance for long-duration wearable therapeutic ultrasound (2013–14). Earlier ultrasound therapy clearances capped treatment at 30 minutes.
• Expanded FDA indications for sam® 2.0: knee osteoarthritis, upper-back myofascial pain, and shoulder, elbow and ankle tendinopathy 
• Funding: NIH (NIMHD) SBIR grants for wearable pain-therapy development. The company also cites NSF, DoD and NASA research funding, and a nationwide insurance-provider network for work-related injuries.

CEO briefing. Founder-CEO Dr. George K. Lewis describes the expanded clearance as a way to "speed injury healing without the need for oral medication, corticosteroids, or surgery" 

MRR's Take: ZetrOZ anchors MRR's Rehabilitation Therapy and Sports Medicine segments, the other mature application. It also fits squarely into the drug-free pain-management theme. For investors, it is the category's evidence-rich, commercially seasoned asset. Expanded indications broaden its reimbursement surface.

4. Sonus Microsystems — The platform option (private, Vancouver)

What it does. The Sonus Patch™ is an AI-enabled wearable imaging patch built on a proprietary polymer MEMS transducer array. It is designed to capture clinical-grade images without a trained sonographer. Cardiac monitoring is its first application.

Public milestones.

• Medtronic collaboration (2026): integrating the Sonus Patch with Medtronic's Acute Care and Monitoring technology in field studies in Kenya.
• ARPA-H MOCS award (July 2026): the patch powers a placental-health test. Clinical evaluation is planned at BC Women's Hospital and Atrium Health 
• Providence Health Care Ventures partnership (2025), followed by a PHCV investment in October 2025.
• Kinetix Medicine clinical trial, scheduled to run from 2026 to 2027.

CEO briefing. President and CEO Dr. Hani Eskandari says the patch was built "so that anyone can capture good ultrasound, not only a trained sonographer" 

MRR's Take: Sonus is the category's platform option. It sits in MRR's PMUT/CMUT-based and AI-assisted technology routes, the routes that unlock imaging rather than single-signal monitoring. A Medtronic collaboration this early is a strong signal of strategic interest. The cardiac beachhead plus the maternal-health extension gives it two shots on goal.

Catalyst Calendar

Five Signals to Watch

1. Recurring revenue mix. Watch the SaaS and consumable share at Pulsenmore, and patch volume per ICU at Flosonics. Recurring revenue is what earns premium valuations in medtech.
2. Group-purchasing reach. Count the hospitals buying FloPatch through Vizient. The contract converts single sales into network-wide decisions.
3. FDA activity. New 510(k) and De Novo filings under ultrasound product codes on the public FDA databases are the earliest public signal of new entrants and expanded indications.
4. Strategic partnerships. Watch for more large-cap device makers following Medtronic into wearable imaging. Each new partnership shortens the path to an acquisition.
5. Public R&D flows. New awards on ARPA-H, NIH RePORTER and SBIR.gov for wearable ultrasound signal the next applications to commercialise.

What the Full Report Adds

The Global Wearable Ultrasound Devices Market Strategic Research Report (80 pages, base year 2025, forecast to 2032) gives investors the detail this brief only outlines:

• Market size and segments: US$30.33M (2025), a 25.9% CAGR, and 2032 scenarios, broken out by technology route, form factor and seven applications
• Geography: five regional and 20+ country-level forecasts
• Company profiles: full profiles of Flosonics Medical, ZetrOZ Systems, Sonus Microsystems and Pulsenmore, covering financial performance (2023–2025), strategy, SWOT and strategic implications for 2026–2032
• Strategy frameworks: a competitive response matrix, Porter's Five Forces, PESTLE, and a chapter on the investment and M&A outlook

Request a free sample → · Need a country-, segment-, or company-specific cut? Request custom research →

Sources

Market data

• Market Research Reports: Global Wearable Ultrasound Devices Market Strategic Research Report. All market size, CAGR, margin, price, and segment figures come from this report.

Government and public bodies

• U.S. SEC: Pulsenmore Form 6-K, FY2025 results
• NIH SEED: ZetrOZ SBIR success story
• ARPA-H MOCS award via UNC Charlotte
• NATO DIANA: Flosonics wearable ultrasound

Company disclosures

• Pulsenmore: FDA De Novo release, H1 2026 results, Investor Deck H1 2026
• Flosonics Medical: Series C, Vizient contract, Sutter Health expansion
• ZetrOZ Systems: Expanded FDA indications
• Sonus Microsystems: ARPA-H award release, Providence Health Care Ventures partnership

Video

• Pulsenmore: FDA authorisation video, App-guided scan demo

Disclaimer: For information only. Based on public disclosures as of October 2026. Not investment advice; please do your own due diligence before investing.